Cargando…
CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
BACKGROUND: Prostate cancer (PCa) is a common malignancy occurring in men. As both an endocrine and gonadal organ, prostate is closely correlated with androgen. So, androgen deprivation therapy (ADT) is effective for treating PCa. However, patients will develop castration-resistant prostate cancer (...
Autores principales: | Chen, Xi, Ma, Junjie, Wang, Xin’an, Zi, Tong, Qian, Duocheng, Li, Chao, Xu, Chengdang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806262/ https://www.ncbi.nlm.nih.gov/pubmed/36601001 http://dx.doi.org/10.3389/fendo.2022.1106175 |
Ejemplares similares
-
Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023) -
The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017) -
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
por: Chen, Xi, et al.
Publicado: (2022) -
Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012) -
A Changing Landscape in Castration-Resistant Prostate Cancer Treatment
por: Felici, A., et al.
Publicado: (2012)